• Users Online: 6246
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe News Contacts Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 6  |  Issue : 3  |  Page : 167-172

Differences in muscle strength, physical activity, and cardiometabolic risk factors between type 2 diabetic patients with and without benzodiazepines or antipsychotic medications


Hamasaki Clinic, Kagoshima, Japan

Correspondence Address:
Dr. Hidetaka Hamasaki
Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 890-0046
Japan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/hm.hm_14_22

Rights and Permissions

Objective: This study aimed to examine differences in muscle strength, physical activity, and cardiometabolic risk factors between Type 2 diabetic patients with and without benzodiazepines (BZD) or antipsychotic drugs (APD). Methods: The author conducted a cross-sectional study on patients with Type 2 diabetes (T2D) whose medication history was collected, and handgrip strength (HGS) was measured. Non-BZD- or APD-users were matched one-to-one with the BZD- or APD-users with respect to their age, gender, and body mass index. The differences in HGS, physical activity, and cardiometabolic risk factors such as blood pressure, lipid profile, and glycemic control between groups were assessed. Results: One hundred and ninety-six patients with and without BZD and 85 patients with and without APD were enrolled. HGS and walking time were significantly lower in patients treated with BZD or APD users than those without BZD or APD. Serum triglycerides levels were higher and high-density lipoprotein cholesterol levels were lower in patients treated with APD than those treated without APD. Both BZD and APD users had a longer sleep duration than nondrug users. Conclusion: BZD and APD were associated with decreased muscle strength and daily physical activity, and APD could impair lipid metabolism in patients with T2D, which may result in increasing the risk of cardiovascular (CV) events. BZDs and APDs should be judiciously prescribed for patients with T2D who are at high risk of CV disease.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1606    
    Printed58    
    Emailed0    
    PDF Downloaded98    
    Comments [Add]    

Recommend this journal